A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Recruiting now · Phase 2/Phase 3

Conditions studied: Non-Small Cell Lung Cancer

In brief

Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan as a monotherapy or in combination with osimertinib compared to standard of care (SOC). Telisotuzumab adizutecan is an investigational drug being developed for the treatment of NSCLC. This study will be divided into two stages, in the first stage (phase 2) participants will receive 1 of 2 doses of telisotuzumab adizutecan as a monotherapy or in combination with osimertinib. In the second stage (phase 3) participants will receive the recommended phase 3 dose (RP3D) of telisotuzumab adizutecan, from the previous stage, or SOC. Approximately 490 adult participants with NSCLC will be enrolled in the study in 200 sites around the world. In phase 2, participants will receive 1 of 2 intravenous (IV) doses of telisotuzumab adizutecan as a monotherapy or in combination with oral osimertinib. In phase 3, participants will receive the IV RP3D of telisotuzumab adizutecan, or SOC. The study will run for a duration of approximately 69 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

Key facts

Study ID

NCT07155187

Run by

AbbVie

People needed

490

Starts

2025-12-10

Expected to finish

2030-09-01

Last updated by the study team

2026-07-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed diagnosis of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with documented EGFR Exon 19 deletion or Exon21 L858R mutation.
• Provide recently obtained tumor tissue during Screening for c-Met immunohistochemistry (IHC) testing (and study stratification in Phase 2). If recently obtained tumor tissue is not available, archived tumor tissue is also acceptable.
• Received one prior third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapy in the adjuvant, locally advanced, or metastatic setting, either as monotherapy or in combination with other agents, and experienced documented radiographic disease progression on or after therapy for the most recent regimen administered prior to study entry. Participant who has received prior third-generation EGFR TKI therapy in the adjuvant setting must have progressed while on treatment.
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.
• At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, that has not been previously irradiated.

You may not qualify if…

• Tumor(s) have adenosquamous or squamous histology or sarcomatoid features.
• Received more than 1 line of systemic therapy in the locally advanced or metastatic setting.
• Active/symptomatic central nervous system (CNS) metastases. Previously treated brain metastases may be included provided they are radiologically stable.
• Evidence of active interstitial lung disease (ILD)/pneumonitis or history of ILD or pneumonitis that required steroids.
• Have any clinically significant medical conditions or any other reason that the investigator determines would interfere with the participant's participation.

Where it is running

• City of Hope National Medical Center /ID# 277005 — Duarte, California, United States (enrolling)
• City of Hope - Orange County Lennar Foundation Cancer Center /ID# 277928 — Irvine, California, United States (enrolling)
• Cancer Specialists of North Florida /ID# 277332 — Jacksonville, Florida, United States (enrolling)
• Cancer Care Centers of Brevard- Rockledge /ID# 277853 — Rockledge, Florida, United States (enrolling)
• Moffitt Cancer Center /ID# 276785 — Tampa, Florida, United States (enrolling)
• Parkview Research Center /ID# 277651 — Fort Wayne, Indiana, United States (enrolling)
• HealthPartners Cancer Research Center /ID# 277339 — Saint Louis Park, Minnesota, United States (enrolling)
• Nho - Revive Research Institute /ID# 277569 — Lincoln, Nebraska, United States (enrolling)
• Dartmouth-Hitchcock Medical Center /ID# 277673 — Lebanon, New Hampshire, United States (enrolling)
• Astera Cancer Care /ID# 277570 — East Brunswick, New Jersey, United States (enrolling)
• Tennessee Cancer Specialists - Knoxville - Old Weisgarber Road /ID# 277891 — Knoxville, Tennessee, United States (enrolling)
• SCRI Oncology Partners /ID# 276959 — Nashville, Tennessee, United States (enrolling)
• Fred Hutchinson Cancer Center. /ID# 277939 — Seattle, Washington, United States (enrolling)
• Northwest Cancer Specialists - Vancouver /ID# 277855 — Vancouver, Washington, United States (enrolling)
• Canberra Hospital /ID# 277166 — Garran, Australian Capital Territory, Australia (enrolling)
• St George Hospital - Kogarah /ID# 277168 — Kogarah, New South Wales, Australia (enrolling)
• Mater Hospital Brisbane /ID# 276985 — South Brisbane, Queensland, Australia (enrolling)
• Icon Cancer Centre Hobart /ID# 277549 — Hobart, Tasmania, Australia (enrolling)
• St Vincent's Hospital Melbourne /ID# 277002 — Fitzroy, Victoria, Australia (enrolling)
• Sunshine Hospital /ID# 276894 — St Albans, Victoria, Australia (enrolling)
• One Clinical Research - Nedlands /ID# 277598 — Nedlands, Western Australia, Australia (enrolling)
• Klinik Floridsdorf /ID# 276679 — Vienna, State of Vienna, Austria (enrolling)
• Institut Jules Bordet /ID# 277283 — Anderlecht, Brussels Capital, Belgium (enrolling)
• Grand Hopital de Charleroi - Les Viviers /ID# 277282 — Charleroi, Hainaut, Belgium (enrolling)
• Highlands Oncology Group - Springdale /ID# 277132 — Springdale, Arkansas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.